A third-generation IMiD for MM

Blood

Volumn 118, Issue 11, 2011, Pages 2931-2932

  Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; IMMUNOMODULATING AGENT; LENALIDOMIDE; MLN 9708; POMALIDOMIDE; SALINOSPORAMIDE A; THALIDOMIDE; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CANCER SURVIVAL; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MULTIPLE MYELOMA; NEUTROPENIA; NOTE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 80052958514     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-364315     Document Type: Note

References (9)

1. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970-2975.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
3. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063- 6073.
4. Mehta J, Cavo M, Singhal S. How I treat elderly patients with myeloma. Blood. 2010;116(13):2215-2223.
5. Bjorklund CC, Wencai M, Zhi-Qiang W, et al. Evidence of a role for activation of Wnt/beta-catenin signalling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286(13):11009-11020.
6. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269-3276. (Pubitemid 41103682)
7. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41-51. (Pubitemid 351350609)
8. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008-5014.
9. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11):1934-1939.